Fareston Raw Powder Toremifene //duosue@chembj.com

Fareston Raw Powder Toremifene //duosue@chembj.com
Keywords:Toremifene,Toremifene powder,Toremifene citrate,Toremifene
Toremifene citrate is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body. Licensed in the United States under the brand name Fareston, toremifene citrate is FDA-approved for use in advanced (metastatic) breast cancer. It is also being evaluated for prevention of prostate cancer under the brand name Acapodene.

Toremifene has been shown to cause a serious type of irregular heartbeat (QT prolongation). QT prolongation can also result in another serious and sometimes fatal type of irregular heartbeat called torsades de pointes, which may also cause fainting or seizures. Do not take toremifene if you have congenital or acquired QT prolongation (long QT syndrome), or if you have low blood potassium or magnesium levels. Certain medicines may increase the risk of irregular heartbeat and should be avoided. Check with your doctor to see if any of your medicines may increase the risk of irregular heartbeat.


How to use toremifene:
Use toremifene as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Toremifene may be taken with or without food.
Do not eat grapefruit or drink grapefruit juice while you use toremifene.
If you miss a dose of toremifene, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use toremifene.

Dosage and Administration
Breast Cancer
PO 60 mg once daily with or without food. Treatment is generally continued until disease progression is observed.

Store between 59° and 86°F. Protect from heat and light.

QT prolongation
Toremifene has been shown to prolong the QTc interval in a dose- and concentration-related manner. Prolongation of the QT interval can result in torsades de pointes, which may result in syncope, seizure, and/or death. Toremifene should not be prescribed to patients with congenital/acquired QT prolongation, uncorrected hypokalemia, or uncorrected hypomagnesemia. Drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be avoided.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s